Question Bank › Conviction backed by things in hand

Conviction backed by things in hand

Conviction backed by things in hand: management stakes the next leg of growth on evidence it already possesses, not cond

Calls Tested
396
Answered YES
29
Hit Rate
7.3%
rare by design

Sabra Health Care REIT, Inc. (SBRA) — this company's answers

NO on the Q1 2023 call 2023-05-04 B
The model's full reasoning — Q1 2023 call → NOWe need to determine if management expresses clear conviction about a step-up ahead and grounds it in concrete things already in hand. Let's analyze the transcript. Key points from management: - Rick Matros: "We're continuing to see traction in operational recovery. Occupancy in our skilled nursing portfolio has now improved every month in the fourth quarter and continued through January. Occupancy October through January in our skilled nursing portfolio improved to 130 basis points. Our skilled mix jumped up dramatically in the first quarter as well. Labor trends are improving, but it's still tough, and it's going to be a bit of a slog there I think for a while, but we're certainly off our highs in terms of inflationary increases and agency utilization. So, we feel good about the progress has been made there as well. EBITDARM coverage without PRF and that's really the only way we think everyone should be looking at it at this point has improved sequentially on a trailing 12-month basis and even more so on a trailing three-month basis." - He mentions specific operators: Signature Health had a tough second half, but first quarter rebounded dramatically. Avamere also strong. Ensign ahead of schedule. - "We're pleased with the proposed 3.7% market basket and we do expect better than historical Medicaid rate increases. Most of those rate increases for our portfolio will be effective on July 1st. We'll have some more clarity probably over the next several weeks on what those rates will be. Our expectation, though, is that some states will be extending COVID rate add-ons and some will update the cost report base year to reflect more current data..." - Investment activity light, but they are focused on transitions. - On Enlivant: terminated position, no impact, transitioning 11 wholly-owned facilities. - Talya: managed senior housing portfolio continued recovery, essentially flat in Q1. Occupancy up 140 bps YoY, but down 100 bps sequentially. REVPOR up 7% YoY. Cash NOI slightly off prior quarter but up 33% YoY. She mentions strong rate growth and continued seasonal occupancy gains. - Michael Costa: normalized FFO per share $0.33, AFFO $0.34, consistent with run rate. No guidance but expects $0.33-$0.34 quarterly run rate. Balance sheet strong.

← Back to the full SBRA analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that conviction in CONCRETE THINGS THE COMPANY ALREADY HAS IN HAND OR ALREADY HAPPENING — rather than in market conditions, industry recovery, or general optimism? Answer YES when BOTH halves come through together in management's own words, as one coherent posture, in whatever form fits the business: (1) STATED CONVICTION ABOUT A STEP-UP AHEAD. Management plainly conveys that it expects the business to be meaningfully bigger, busier, or stronger over roughly the coming year — not merely steady continuation, and not vague aspiration. The conviction should be unmistakable in how management talks about where the company is headed: confident, specific in direction, and owned by management itself. (2) THE CONVICTION RESTS ON EVIDENCE ALREADY IN THE COMPANY'S POSSESSION. When management explains WHY it is confident, it points to real, present-tense substance — in whatever form fits the industry — such as: business already won, signed, booked, or committed that has not yet fully shown up in results; work, orders, customers, or volumes already arriving or ramping now; a capability, capacity, product, or asset already built or in place that the growth will run through; observable customer behavior already occurring; or progress already made that management can describe concretely. The evidence should be specific enough that management is describing things that exist and can be pointed to, not projections, pipeline hopes, or a market thesis. Where analysts probe or doubt, management responds with this kind of already-real substance rather than with reassurance alone. Answer NO if management's confidence rests mainly on expected market recovery, industry tailwinds, macro improvement, pricing environments, seasonal patterns, or customer sentiment that has not yet converted into anything the company holds. NO if the forward talk is generic optimism, mission language, or big-market framing without concrete present-tense support. NO if the call conveys steady continuation, a defense of weak results, or a turnaround still promised rather than evidenced. NO if the evidence offered is only a raised financial guidance number, an analyst's model, or third-party forecasts. NO if the conviction and the evidence never connect — strong facts reported but no stated step-up ahead, or a stated step-up with nothing in hand behind it. NO if the posture appears only in an analyst's question or characterization that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
OEC Orion Engineered Carbons S.A. Q4 2022 2023-02-17 B+
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
CUE Cue Biopharma, Inc. Q3 2022 2022-11-14 D
ZVIA Zevia PBC Q1 2022 2022-05-12 B
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
LC LendingClub Corporation Q4 2021 2022-01-26 A
OOMA Ooma, Inc. Q3 2022 2021-12-02 B+
KTB Kontoor Brands, Inc. Q3 2021 2021-11-04 A
CMTL Comtech Telecommunications Corp. Q1 2019 2018-12-07 B+
PRPO Precipio, Inc. Q3 2018 2018-11-19 D
ALB Albemarle Corporation Q3 2018 2018-11-08 B
WES Western Midstream Partners, LP Q3 2018 2018-10-31 D
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
LRN Stride, Inc. Q1 2019 2018-10-23 B
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
FSS Federal Signal Corporation Q1 2018 2018-05-12 A
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
INSM Insmed Incorporated Q4 2017 2018-02-23 B
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
FLEX Flex Ltd. Q1 2018 2017-07-28 F
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
ANIP ANI Pharmaceuticals, Inc. Q4 2016 2017-03-02 B+
GPOR Gulfport Energy Corporation Q4 2016 2017-02-14 A
WYY WidePoint Corporation Q3 2016 2016-11-09 D
LBTYK Liberty Global's Q1 2016 2016-05-10 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

CUE · Q3 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up to a meaningfully higher level, citing the recent $30M PIPE financing, Fast Track designation, emerging clinical data from CUE-101 monotherapy and combination trials, and the derisked Immuno-STAT platform as concrete assets already in hand that support advancing toward 2024 clinical development and potential registration paths. They ground this in present-tense facts such as the SITC data, cash runway extension, first CUE-102 patient dosed, and ongoing trial expansions rather than external market or industry conditions.
BFIN · Q1 2022 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction that the business is stepping up: they have already achieved and exceeded the $40 million quarterly loan growth goal, are targeting $1.125–$1.150 billion in Q2 (with a reach to $1.2 billion by year-end), and expect EPS of $0. 14–$0.16 in Q2 rising $0.03–$0.05 per quarter thereafter, with ROE potentially in the 80s–90s run-rate by early 2023. This conviction rests on concrete, already-real evidence in hand: $45 million loan growth already booked in April 2022 (portfolio now over $1.
ALLY · Q1 2018 → YESThe question is: Does management express CLEAR CONVICTION that the company's business is stepping up to a meaningfully higher level over the coming quarters, AND does it consistently ground that convi...YES Management states clear conviction of a step-up: “we see these metrics meaningfully higher on a year-over-year basis, and that will fully continue over the medium term,” “adjusted EPS growth of 20% to 30% for the year,” “we expect net financing revenue to move higher,” “expect to see acceleration in this line item in Q2 and throughout the rest of 2018,” and “keeps us on the path to delivering our 2018 outlook.” That conviction is grounded in concrete, already-present items: record $9.

More from the question bank

Room to raise the ceilingSelling the shovels to a customer who just gStaircase quarter: best recent period just rCommitment step-up grounded in demand alreadCheap-to-serve incremental businessTheir own money is on the lineAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.